Figure 1.

ERK1/2 dephosphorylation in early and late AA TN xenografts and patient-derived xenografts. 100 µg of total lysates obtained from HCC70 cells, or HCC70 xenografts from small (S) (2 weeks) and large (L) (8 weeks) growth and patient-derived xenografts (PDX) (4 months) (A), or HCC1806 xenografts (B) or HMLE^HRASV12 (HRAS) (C) were analyzed by western blot to compare various proteins involved in MAP kinase signaling pathways. (D) 100 µg of total cell lysates obtained from large (L), small (S), L/S (equal amounts of L and S lysates incubated at 37°C for 1 hr), L/S/H (L+S mixture heated at 100°C for 15-30 mins), and L/S/I (L+S mixture incubated with 10 or 20 µM sodium orthovanadate and incubated at 37°C for 1 hr) xenografts obtained from HRAS were analyzed by western blot analysis. (E) 100 µg of total cell lysates obtained from HRAS late tumors (HRAS L1 and HRAS L2), and either small (TN/S) or large (TN/L) HCC70 tumors alone or in combination with HRAS L1 followed by incubated at 37°C for 1 hr and analyzed for total ERK1/2 or phosphorylated ERK1/2 by western blot analysis. Experiments were replicated three times and a representative panel has been shown.